1st Vall d'Hebron Ventures Summit

El VHIR organitza la primera trobada entre emprenedors i l’ecosistema inversor.

07/05/2024

The first Vall d'Hebron Ventures Summit took place on May 6th. It is a meeting organised by VHIR to bring together its spin-offs and their corresponding investors, with the aim of building a community among them. Although many already know each other because they have met at other events, VHIR aims to be the link that reinforces the ties and provides visibility to all the stakeholders. 

On this event, fifteen of our spin-offs were briefly presented: Imidomics (Sara Marsal, CMO), Bsure Medical (Menno Marien), Mimark Diagnostics (Marina Rigau), Endolipid Therapeutics & Endolipid Derma (David Martínez-Selva, CSO), Tensor Medical (Sergi Valverde), Frontwave (Cristina Duran),  Nora Health (Ariadna Oroval), Abcdx (Jean-Charles Sanchez), Manina Medtech (Mónica Rodríguez, vídeo), D-Sight (Carla Maté), heecap (Laura Lizama), Ysotope theranostics (Carlos Langeberg), Artis Development (Raul Guerra), Trackyourmed (Oriol Bestard). Thus, the attendees were able to get an overview of what the entrepreneurs are working on and the current stage they are at. 

The round panel ‘The 3 perspectives of an investment round’ exposed the three visions of this stage which often generates conflict between investors and entrepreneurs. Participants included Marina Rigau, CEO and co-founder of MiMARK, Laura Rodríguez, investor at Invivo Partners, and Antoni Rosselló, lawyer at RCD. In fact, lawyers also play a very significant role mediating and supporting during all the stages of the investment rounds. 

In addition, other investors were invited in order they could learn about new opportunities in this community. The event was also opened to all the Campus Vall d'Hebron researchers in order to encourage entrepreneurialism. 

This meeting was created to become an annual event of reference in the sector to facilitate the recruitment of both national as well as international investors of and for our companies. According to Rafael Navajo, Director of Innovation and Business Development at the VHIR, "it is a unique opportunity to create a network of connections between different environments, which will help us maintain our position as a reference centre in innovation management. It also allows us to continue positively impacting patient society'.

Una trobada per reunir a les seves spin-off i els seus corresponents inversors amb l’objectiu de crear una comunitat entre ells.

Share it:

Notícies relacionades

Related activities

II Jornada unidad de enfermedades autoinmunes sistémicas del servicio de medicina interna

06/20/2024 - 08:00
Unidad de Enfermedades Autoinmunes Sistémicas
More information

LGTBQIA+ Community at VHIR – Equality, diversity and inclusion in health research institutions

06/20/2024 - 12:00
More information

4º curso angioedema basado en simulación

Vall d’Hebron Centre de Simulació Clínica Avançada Pl. 5a Hospital de Traumatologia. Hospital Universitari Vall d’Hebron
06/26/2024 - 15:00
Dirigido a residentes de 3r y 4t año de Alergología
More information

Curso facilitadores en simulación virtual: plataforma SIMOONS

06/26/2024 - 16:00
Simulación Clínica
More information

Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.